Primary-outcome results across pivotal trials
Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.
| Trial | Indication | Primary endpoint | Arm | Value |
|---|---|---|---|---|
| NCT00069095 | Colorectal Neoplasms | PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone Baseline until disease progression or death, approximately 2 years 6 months | FOLFOX-4+BV/XELOX+BV | 285.0 days |
| FOLFOX-4+P/XELOX+P | 244.0 days | |||
| NCT00069095 | Colorectal Neoplasms | Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4 Baseline until disease progression or death, approximately 2 years 6 months | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | 259 days |
| XELOX/XELOX+P/XELOX+BV | 241 days | |||
| NCT00096278 | Colonic Neoplasms | Disease-free Survival 3 years | Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 percentage of patients |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 percentage of patients | |||
| NCT00101686 | Colorectal Neoplasms | Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL every 6 weeks until disease progression | FOLFIRI | 8.18 months |
| mIFL | 6.01 months | |||
| NCT00110214 | Prostatic Neoplasms | Overall Survival Duration of study (up to 5 years) | Docetaxel + Bevacizumab | 22.6 months |
| Docetaxel + Placebo | 21.5 months | |||
| NCT00112918 | Colorectal Neoplasms | Disease-free Survival in Stage III Cancer Patients - Number of Events From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized). | FOLFOX4 | 17 participants |
| FOLFOX4 | 3 participants | |||
| FOLFOX4 | 219 participants | |||
| FOLFOX4 | 237 participants | |||
| FOLFOX4 | 718 participants | |||
| FOLFOX4 + Bv | 21 participants | |||
| FOLFOX4 + Bv | 253 participants | |||
| FOLFOX4 + Bv | 8 participants | |||
| FOLFOX4 + Bv | 680 participants | |||
| FOLFOX4 + Bv | 280 participants | |||
| XELOX+Bv | 25 participants | |||
| XELOX+Bv | 253 participants | |||
| XELOX+Bv | 223 participants | |||
| XELOX+Bv | 6 participants | |||
| XELOX+Bv | 699 participants | |||
| NCT00112918 | Colorectal Neoplasms | Disease-free Survival in Stage III Cancer Patients - Time to Event From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized). | FOLFOX4 | NA months |
| FOLFOX4 + Bv | NA months | |||
| XELOX+Bv | NA months | |||
| NCT00115765 | Colorectal Neoplasms | Objective Tumor Response Through Week 12 (Irinotecan) Overall Study | Irinotecan and Bevacizumab Plus Panitumumab | 29 Participant |
| Irinotecan and Bevacizumab Without Panitumumab | 27 Participant | |||
| NCT00115765 | Colorectal Neoplasms | Progression-Free Survival (Oxaliplatin) Overall study | Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 Month |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 Month | |||
| NCT00130728 | Carcinoma, Non-Small-Cell Lung | Overall Survival (OS) Among All Randomized Patients From the date of randomization until the date of patient death from any cause, or the date of last contact. (Up to 3.1 years) | Erlotinib HCl + Bevacizumab | 9.3 months |
| Erlotinib HCl + Placebo | 9.2 months | |||
| NCT00217737 | Colonic Neoplasms | Disease-free Survival Rate at 5 Years Assessed every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization | Arm A (5-FU, Leucovorin, Oxaliplatin) | 0.805 Proportion of participants |
| Arm B (5-FU, Leucovorin, Oxaliplatin, Bevacizumab) | 0.833 Proportion of participants | |||
| Arm C (Observation) | 0.816 Proportion of participants | |||
| NCT00227617 | Neoplasms | Best Objective Response From Baseline until disease progression, up to 8 years | Combined Neuroendocrine Tumors | 64 percentage of participants |
| Combined Neuroendocrine Tumors | 31 percentage of participants | |||
| Combined Neuroendocrine Tumors | 2.8 percentage of participants | |||
| Combined Neuroendocrine Tumors | 2.8 percentage of participants | |||
| NCT00227617 | Neoplasms | Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years | Carcinoid | 3 Participants |
| PDNEC | 0 Participants | |||
| PNET | 3 Participants | |||
| NCT00252564 | Colorectal Neoplasms | Progression-Free Survival (PFS) 12 months | Arm A | 11.0 months |
| Arm B | 8.3 months | |||
| NCT00252564 | Colorectal Neoplasms | Progression-free Survival (PFS) Rate at 1 Year. 12 months | Arm A | 0.45 proportion of participants w/ PFS at 1yr |
| Arm B | 0.32 proportion of participants w/ PFS at 1yr | |||
| NCT00257608 | Carcinoma, Non-Small-Cell Lung | Progression-free Survival (PFS) Approximately 3 years | Bevacizumab + Erlotinib | 4.8 months |
| Bevacizumab + Placebo | 3.7 months | |||
| NCT00262067 | Breast Neoplasms | Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months) | Bevacizumab 15 mg/kg + Capecitabine | 8.6 Months |
| Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen | 9.2 Months | |||
| Placebo to Bevacizumab + Capecitabine | 5.7 Months | |||
| Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen | 8.0 Months | |||
| NCT00262847 | Ovarian Neoplasms | Progression-free Survival From study entry until first disease progression, death or date of last contact, up to 6 years | Arm I (Placebo, Paclitaxel, Carboplatin) | 11.0 months |
| Arm II (Placebo, Paclitaxel, Carboplatin, Bevacizumab) | 12.3 months | |||
| Arm III (Paclitaxel, Carboplatin, Bevacizumab) | 15.3 months | |||
| NCT00265850 | Colorectal Neoplasms | Overall Survival Up to 5 years post-treatment | Arm A: FOLFOX or FOLFIRI + Bevacizumab | 29.0 months |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 30.0 months | |||
| NCT00281697 | Breast Neoplasms | Progression-free Survival Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months) | Standard Chemotherapy + Bevacizumab | 7.2 Months |
| Standard Chemotherapy + Placebo | 5.1 Months | |||
| NCT00303628 | Rectal Neoplasms | 5-year Overall Survival Rate Follow-up assessments performed every 3 months for patients < 2 years from randomization, every 6 months for patients 2-5 years from randomization, and every 12 months for patients 5-10 years from randomization | Arm I (Oxaliplatin, Fluorouracil, Leucovorin) | 0.883 proportion of participants |
| Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab) | 0.837 proportion of participants | |||
| NCT00324805 | Carcinoma, Non-Small-Cell Lung | Overall Survival From registration to death, up to 10 years | Arm I (Chemotherapy) | NA months |
| Arm II (Chemotherapy, Bevacizumab) | 85.8 months | |||
| NCT00324987 S0502 | Gastrointestinal Stromal Tumors | Progression Free Survival Up to 7 years | Imatinib | 81 months |
| Imatinib + Bevacizumab | 30 months | |||
| NCT00333775 | Breast Neoplasms | Progression-free Survival Baseline to the 15 Sep 2008 cut-off date (up to 2 years, 6 months) | Docetaxel 100 mg/m^2 Plus Bevacizumab 15.0 mg/kg | 8.8 Months |
| Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg | 8.7 Months | |||
| Docetaxel 100 mg/m^2 Plus Placebo | 8.0 Months | |||
| NCT00349336 | Colorectal Neoplasms | Weekly Steady-state Exposure of Bevacizumab Up to 48 weeks | FOLFOX-4+Bevacizumab | 4022.4 day*ug/mL (±1774.2 Standard Deviation) |
| XELOX+Bevacizumab | 4090.3 day*ug/mL (±1047.6 Standard Deviation) | |||
| NCT00373256 | Breast Neoplasms | Progression-Free Survival (PFS) From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death | Bevacizumab + Paclitaxel | 9.2 Months |
| Sunitinib + Paclitaxel | 7.4 Months | |||
| NCT00384176 HORIZON III | Colorectal Neoplasms | Progression Free Survival Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression | Bevacizumab 5 mg/kg | 10.3 Months |
| Cediranib 20 mg | 9.9 Months | |||
| NCT00391092 | Breast Neoplasms | Progression Free Survival (PFS) Every 9 weeks up to Week 36, thereafter every 12 weeks until disease progression (up to the clinical cutoff of 30 June 2011, up to 4.75 years) | Trastuzumab + Bevacizumab + Docetaxel | 16.5 months |
| Trastuzumab + Docetaxel | 13.7 months | |||
| NCT00408408 | Breast Neoplasms | Pathologic Complete Response (pCR) of the Primary Tumor in the Breast Time of surgery, on average 6 or 13 months | Arm 1A: Docetaxel Then AC | 33.7 percentage of patients |
| Arm 1B Docetaxel + Bev Then AC + Bev | 31.6 percentage of patients | |||
| Arm 2A: Docetaxel + Capecitabine Then AC | 23.5 percentage of patients | |||
| Arm 2B: Docetaxel + Cape + Bev Then AC + Bev | 36.1 percentage of patients | |||
| Arm 3A: Docetaxel + Gem Then AC | 27.6 percentage of patients | |||
| Arm 3B: Docetaxel + Gem + Bev Then AC + Bev | 35.8 percentage of patients | |||
| NCT00433511 | — | Invasive Disease-free Survival (IDFS) Rate at 5 Years Assessed at 5 years | Arm A (Chemo + Placebo) | 0.77 proportion of participants |
| Arm B (Chemo + Bevacizumab) | 0.76 proportion of participants | |||
| Arm C (Chemo + Bevacizumab Then Bevacizumab Monotherapy) | 0.80 proportion of participants | |||
| NCT00434642 OCEANS | Ovarian Neoplasms | Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) From randomization through September 17, 2010 (up to 3 years, 5 months) | Carboplatin and Gemcitabine + Bevacizumab | 12.4 Months |
| Carboplatin and Gemcitabine + Placebo | 8.4 Months | |||
| NCT00448591 | Breast Neoplasms | Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs) Day 1 of Cycles 1, 2, 3, 4, 5, and 6 up to 6 months after the last bevacizumab infusion | Bevacizumab | 95.4 percentage of participants |
| Bevacizumab | 57.6 percentage of participants | |||
| Bevacizumab | 64.2 percentage of participants | |||
| Bevacizumab | 29.7 percentage of participants | |||
| Bevacizumab | 7.6 percentage of participants | |||
| Bevacizumab | 53.1 percentage of participants | |||
| Bevacizumab | 71.8 percentage of participants | |||
| NCT00484939 | Colorectal Neoplasms | Progression-free Survival Baseline to the end of the study (up to 5 years 8 months) | Bevacizumab + Capecitabine | 9.1 Months |
| Capecitabine | 5.1 Months | |||
| NCT00486759 | Lymphoma, B-Cell | Progression-free Survival (PFS) Baseline to end of the study (up to 4 years, 4 months) | Bevacizumab + Rituximab + CHOP | 40.2 Months |
| Placebo + Rituximab + CHOP | 42.9 Months | |||
| NCT00499369 | Rectal Neoplasms | Progression-free Survival (PFS) Up to 5 years | Cohort I: Chemotherapy + Cetuximab | 3.2 months |
| Cohort I: Chemotherapy + Cetuximab + Higher Bevacizumab | 8.5 months | |||
| Cohort I: Chemotherapy + Cetuximab + Lower Bevacizumab | 4.2 months | |||
| Cohort II: Chemotherapy + Bevacizumab | 5.6 months | |||
| Cohort II: Chemotherapy + Cetuximab | 1.4 months | |||
| NCT00520975 | Breast Neoplasms | Progression-free Survival assessed every 3 months for patients within 2 years of registration, every 6 months for patients 3-5 years from registration and then yearly for up to10 years | Arm A (Chemotherapy and Placebo) | 11.1 Months |
| Arm B (Chemotherapy and Bevacizumab) | 13.8 Months | |||
| NCT00528567 | Breast Neoplasms | Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Event driven (until data cutoff: 29 February 2012 up to 49 months) | Bevacizumab and Chemotherapy | 14.5 Percentage of participants |
| Bevacizumab and Chemotherapy | 85.5 Percentage of participants | |||
| Chemotherapy | 15.9 Percentage of participants | |||
| Chemotherapy | 84.1 Percentage of participants | |||
| NCT00528567 | Breast Neoplasms | Percentage of Participants With Invasive Disease-free Survival (IDFS) Events Excluding Second Primary Non-Breast Invasive Cancer Event driven (until data cutoff: 29 February 2012: up to 49 months) | Bevacizumab and Chemotherapy | 86.5 Percentage of participants |
| Bevacizumab and Chemotherapy | 13.5 Percentage of participants | |||
| Chemotherapy | 85.3 Percentage of participants | |||
| Chemotherapy | 14.7 Percentage of participants | |||
| NCT00528567 | Breast Neoplasms | Time to Invasive Disease-free Survival (IDFS) Event Event driven (until data cutoff: 29 February 2012: up to 49 months) | Bevacizumab and Chemotherapy | NA Months |
| Chemotherapy | NA Months | |||
| NCT00528567 | Breast Neoplasms | Time to Invasive Disease-free Survival (IDFS) Event Excluding Second Primary Non-Breast Invasive Cancer Event driven (until data cutoff: 29 February 2012: up to 49 months) | Bevacizumab and Chemotherapy | NA Months |
| Chemotherapy | NA Months | |||
| NCT00545077 | Breast Neoplasms | Progression-free Survival (PFS) Up to 2 years | Arm A: Endocrine Therapy (ET) | 14.4 Months |
| Arm B: ET With Bevacizumab (ET-B) | 19.3 Months | |||
| NCT00548548 AVAGAST | Adenocarcinoma | Overall Survival From randomization until death, up to 26 months | Bevacizumab | 12.1 months |
| Placebo | 10.1 months | |||
| NCT00565851 | Ovarian Neoplasms | To Determine if Surgical Secondary Cytoreduction in Addition to Adjuvant Chemotherapy Increases the Duration of Overall Survival in Patients With Recurrent Platinum Sensitive Epithelial Ovarian Cancer, Peritoneal Primary or Fallopian Tube Cancer The time frame is 82.5 months (median duration of follow-up) | Cytoreductive Surgery | 50.6 Months |
| No Cytoreductive Surgery | 64.7 Months | |||
| NCT00565851 | Ovarian Neoplasms | To Determine if the Addition of Bevacizumab Increases the Duration of Overall Survival Relative to Second-line Paclitaxel and Carboplatin Alone in Patients With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Primary or Fallopian Tube Cancer The time frame is 82.5 months (median duration of follow-up). | Paclitaxel and Carboplatin Chemotherapy | 37.3 Months |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 42.2 Months | |||
| NCT00569127 | Neuroendocrine Tumors | Central Review-based Progression-Free Survival Up to 3 years | Octreotide, Bevacizumab | 16.6 months |
| Octreotide, Interferon Alpha-2b | 15.4 months | |||
| NCT00588770 | Squamous Cell Carcinoma of Head and Neck | Overall Survival (OS) assessed every 3 months within 2 years from study entry, then every 6 months up to 5 years from study entry | Chemotherapy Arm (Arm A) | 11.0 months |
| Chemotherapy+Bevacizumab (Arm B) | 12.6 months | |||
| NCT00593450 | Macular Degeneration | Change From Baseline in Visual-acuity Score (Continuous) Baseline and 1 Year | 1-Lucentis Monthly | 8.5 No. of Letters (±14.1 Standard Deviation) |
| 2-Avastin Monthly | 8.0 No. of Letters (±15.8 Standard Deviation) | |||
| 3-Lucentis as Needed | 6.8 No. of Letters (±13.1 Standard Deviation) | |||
| 4-Avastin as Needed | 5.9 No. of Letters (±15.7 Standard Deviation) | |||
| NCT00600340 TURANDOT | Breast Neoplasms | Overall Survival (ITT Population) Time from the date of randomization to the date of death or date last known to be alive, assessed up to approximately 6 years | Bevacizumab Plus Capecitabine | 26.0 months |
| Bevacizumab Plus Paclitaxel | 29.5 months | |||
| NCT00600340 TURANDOT | Breast Neoplasms | Overall Survival (PP Population) Time from the date of randomization to the date of death or date last known to be alive, assessed up to approximately 6 years | Bevacizumab Plus Capecitabine | 26.1 months |
| Bevacizumab Plus Paclitaxel | 30.2 months | |||
| NCT00601900 | Breast Neoplasms | Progression-free Survival From randomization until disease progression or death whichever occurs first, assessed up to 5 years | Arm I (Endocrine Therapy With Monoclonal Antibody) | 20.2 months |
| Arm II (Endocrine Therapy) | 15.6 months | |||
| NCT00623805 | Colorectal Neoplasms | Progression-free Survival Baseline to the end of the study (up to 4 years, 2 months) | Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C | 12.6 Months (±1.0 Standard Error) |
| Bevacizumab+Capecitabine+Oxaliplatin | 9.0 Months (±0.7 Standard Error) | |||
| NCT00631371 INTORACT | Carcinoma, Renal Cell | Progression-Free Survival (PFS): Independent-Assessment Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012) | Bevacizumab+ Interferon-Alfa | 9.3 months |
| Bevacizumab+Temsirolimus | 9.1 months | |||
| NCT00700102 | Colorectal Neoplasms | Overall Survival: Time From Randomization to Death From Any Cause within 6.5 years | Chemotherapy | 9.8 months |
| Chemotherapy + Bevacizumab | 11.2 months | |||
| NCT00738530 | Carcinoma, Renal Cell | Overall Survival (OS) Duration Baseline until death (up to 4.25 years) | Bevacizumab + IFN-Alfa-2A | 23.3 months |
| Placebo + IFN-Alfa-2A | 21.3 months | |||
| NCT00738530 | Carcinoma, Renal Cell | Percentage of Participants Who Died Baseline up to 4.25 years | Bevacizumab + IFN-Alfa-2A | 67.3 percentage of participants |
| Placebo + IFN-Alfa-2A | 69.6 percentage of participants | |||
| NCT00762034 | Carcinoma, Non-Small-Cell Lung | Overall Survival Baseline to date of death from any cause (up to 37.06 months) | Pac/Carbo/Bev | 13.40 months |
| Pem/Carbo/Bev | 12.55 months | |||
| NCT00785291 | Breast Neoplasms | Progression Free Survival Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years) | Arm A (Paclitaxel) | 10.97 months |
| Arm B (Nab-paclitaxel) | 9.3 months | |||
| Arm C (Ixabepilone) | 7.36 months | |||
| NCT00803062 | Uterine Cervical Neoplasms | Overall Survival From entry into the study to death or the date of last contact, assessed up to 5 years | Arm I (Paclitaxel and Cisplatin) | 14.26 months |
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 17.51 months | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 12.68 months | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 16.20 months | |||
| NCT00803062 | Uterine Cervical Neoplasms | Progression-free Survival From study entry until disease progression, death or date of last contact, assessed up to 5 years (During treatment: every 3 weeks if by physical exam, every 6 weeks by CXR, CT or MRI. In follow-up: quarterly for 2 years then semi-annually for 3 years) | Arm I (Paclitaxel and Cisplatin) | 6.67 months |
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 9.63 months | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 5.29 months | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 7.36 months | |||
| NCT00803062 | Uterine Cervical Neoplasms | To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study. From date of enrollment until 30 days after treatment completion | Arm I (Paclitaxel and Cisplatin) | 4 Participants |
| Arm I (Paclitaxel and Cisplatin) | 6 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 1 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 12 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 48 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 9 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 0 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 33 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 3 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 8 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 22 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 2 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 17 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 3 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 2 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 21 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 8 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 1 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 18 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 0 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 34 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 10 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 3 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 0 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 4 Participants | |||
| Arm I (Paclitaxel and Cisplatin) | 4 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 9 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 30 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 4 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 12 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 16 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 1 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 29 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 4 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 2 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 8 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 8 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 0 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 29 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 61 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 5 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 5 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 7 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 16 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 0 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 48 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 2 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 17 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 18 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 0 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 23 Participants | |||
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 1 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 2 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 5 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 1 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 1 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 0 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 48 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 1 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 7 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 1 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 11 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 5 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 6 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 11 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 23 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 0 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 0 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 7 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 61 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 19 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 2 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 4 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 5 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 22 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 6 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 13 Participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 2 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 17 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 4 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 16 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 0 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 1 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 14 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 0 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 22 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 2 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 7 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 6 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 30 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 79 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 9 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 14 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 9 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 66 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 4 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 1 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 2 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 27 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 30 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 1 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 2 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 3 Participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 9 Participants | |||
| NCT00803062 | Uterine Cervical Neoplasms | Tumor Response Every cycle (if assessed by physical exam), every other cycle (if assessed by imaging), after the final cycle, then every 3 months x 2 years, then every 6 months x 3 years up to 5 years. | Arm I (Paclitaxel and Cisplatin) | 44.74 percentage of participants |
| Arm II (Paclitaxel, Cisplatin, Bevacizumab) | 49.57 percentage of participants | |||
| Arm III (Topotecan Hydrochloride and Paclitaxel) | 27.03 percentage of participants | |||
| Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab) | 47.32 percentage of participants | |||
| NCT00853073 Avastin | Glaucoma | Intraocular Pressure (IOP) 6 months | Treatment A (Bevacizumab) | 11.52 mmHg (millimeters of mercury) |
| Treatment B (Balanced Salt Solution) | 12.83 mmHg (millimeters of mercury) | |||
| NCT00884741 | Glioblastoma | Overall Survival (OS) From randomization to date of death or last follow-up. Analysis occurs after all 390 deaths have been reported. | Randomized Arm 1: TMZ+RT + Placebo | 16.1 months |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 15.7 months | |||
| NCT00884741 | Glioblastoma | Progression-free Survival (PFS) From randomization to date of progression, death, or last follow-up for progression-free survival. Analysis occurs after all 390 deaths have been reported. | Randomized Arm 1: TMZ+RT + Placebo | 7.3 months |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 10.7 months | |||
| NCT00887822 AVATAR | Stomach Neoplasms | Overall Survival From randomization until death (up to 34 months) | Bevacizumab, Capecitabine and Cisplatin | 10.5 months |
| Placebo, Capecitabine and Cisplatin | 11.4 months | |||
| NCT00887822 AVATAR | Stomach Neoplasms | Percentage of Participants With Event (Death) From randomization until death (up to 34 months) | Bevacizumab, Capecitabine and Cisplatin | 77.0 percentage of participants |
| Placebo, Capecitabine and Cisplatin | 75.5 percentage of participants | |||
| NCT00911170 | Colorectal Neoplasms | Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle) | Pegfilgrastim | 2.4 percentage of participants |
| Placebo | 5.7 percentage of participants | |||
| NCT00929240 | Breast Neoplasms | Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013) Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years | Maintenance Phase: Bevacizumab | 88.3 percentage of participants |
| Maintenance Phase: Bevacizumab + Capecitabine | 75.8 percentage of participants | |||
| NCT00929240 | Breast Neoplasms | Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013) Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years | Maintenance Phase: Bevacizumab | 4.3 months |
| Maintenance Phase: Bevacizumab + Capecitabine | 11.9 months | |||
| NCT00942331 | Prostatic Neoplasms | Overall Survival (OS) From date of randomization to date of death due to any cause, assessed up to 7 years | Arm I (GCP) | 14.3 months |
| Arm II (GCB) | 14.5 months | |||
| NCT00943826 | Glioblastoma | Co-Primary: Overall Survival (OS) Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months]) | Bevacizumab + RT + Temozolomide | 16.8 Months |
| Placebo + RT + Temozolomide | 16.7 Months | |||
| NCT00943826 | Glioblastoma | Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months) | Bevacizumab + RT + Temozolomide | 10.6 Months |
| Placebo + RT + Temozolomide | 6.2 Months | |||
| NCT00946712 | Adenocarcinoma of Lung | Overall Survival (OS) in the Entire Study Population Patients will be followed every 3 weeks while on protocol treatment. Once off all protocol treatment, patients will be followed every 6 months until death or up to 3 years | Arm I (Chemo +/- Bevacizumab) | 9.2 months |
| Arm II (Chemo, Cetuximab, +/- Bevacizumab) | 10.9 months | |||
| NCT00946712 | Adenocarcinoma of Lung | Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional Review Disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression. | Arm I (Chemo +/- Bevacizumab) | 4.8 months |
| Arm II (Chemo, Cetuximab, +/- Bevacizumab) | 5.4 months | |||
| NCT00948675 | Carcinoma, Non-Small-Cell Lung | Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Randomization to measured progressive disease or treatment discontinuation up to 39.49 months | Paclitaxel + Carboplatin + Bevacizumab | 2.86 months |
| Pemetrexed + Carboplatin | 3.91 months | |||
| NCT00951496 | Brenner Tumor | Median Progression-free Survival Progression-free survival is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years. | Arm I (Paclitaxel, Carboplatin, Bevcizumab IV) | 24.9 months |
| Arm II (Paclitaxel,carboplatinIP, Bevacizumab IP) | 27.3 months | |||
| Arm III (Paclitaxel IP, Cisplatin, Bevacizumab) | 26.0 months | |||
| NCT00961415 | — | Progression Free Survival During Maintenance Treatment Phase Up to 21 months | Bevacizumab +Pemetrexed Maintenance Trt Arm B | 10.2 Months |
| Bevacizumab Maintenance Trt Arm A | 6.6 Months | |||
| NCT00976456 65plus | Lung Neoplasms | Progression Free Survival 42 months | Bevacizumab + Pemetrexed | 4.8 months |
| Bevacizumab + Pemetrexed + Carboplatin | 6.8 months | |||
| NCT00976911 | Ovarian Neoplasms | Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011) Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011 | Chemotherapy | 92.3 percentage of participants |
| Chemotherapy + Bevacizumab | 78.8 percentage of participants | |||
| NCT00976911 | Ovarian Neoplasms | Progression Free Survival (PFS; Data Cutoff 14 November 2011) Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011 | Chemotherapy | 3.4 months |
| Chemotherapy + Bevacizumab | 6.8 months | |||
| NCT01012297 | — | Progression-free Survival From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Arm I Gem+Doce+Placebo | 6.2 months |
| Arm II Gem+Doce+Bev | 4.2 months | |||
| NCT01081262 | Ovarian Neoplasms | Overall Survival Up to five years | Arm I (Carboplatin and Paclitaxel) | 37.6 months |
| Arm II (Oxaliplatin and Capecitabine) | 27.8 months | |||
| Arm III (Carboplatin, Paclitaxel, Bevacizumab) | 27.7 months | |||
| Arm IV (Oxaliplatin, Capecitabine, Bevacizumab) | 55.7 months | |||
| NCT01107626 | Carcinoma, Non-Small-Cell Lung | Overall Survival Assessed every 6 weeks during induction therapy and every 3 cycles during maintenance therapy; after discontinuation of study therapy, assessed every 3 months for 2 years and every 6 months for years 3-5 | Arm A (Induction Then Maintenance With Bevacizumab) | 14.4 months |
| Arm B (Induction Then Maintenance With Pemetrexed | 15.9 months | |||
| Arm C (Induction Then Maintenance With Bevacizumab and Pemetrexed) | 16.4 months | |||
| NCT01167712 | Fallopian Tube Neoplasms | Progression-Free Survival The timeframe is from enrollment onto the study up to 3 years following enrollment. | Arm I (Adjuvant Chemotherapy Suboptimally Debulked) | 14.7 months |
| Arm II (Neoadjuvant Chemotherapy) | 14.0 months | |||
| NCT01169558 | Colorectal Neoplasms | Safety: Number of Participants With Serious and Specific Adverse Events Up to approximately 3 years | Bevacizumab | 57 participants |
| Bevacizumab | 2 participants | |||
| Bevacizumab | 2 participants | |||
| Bevacizumab | 2 participants | |||
| Bevacizumab | 5 participants | |||
| Bevacizumab | 6 participants | |||
| Bevacizumab | 22 participants | |||
| Bevacizumab | 42 participants | |||
| Bevacizumab | 50 participants | |||
| NCT01198158 | Carcinoma, Renal Cell | Overall Survival (OS) The time from date of randomization to date of death due to any cause, assessed up to 5.5 years | Arm I (Everolimus) | 27.5 months |
| Arm II (Everolimus With Bevacizumab) | 21.8 months | |||
| NCT01214720 | Pancreatic Neoplasms | Duration of Overall Survival - Percentage of Participants With an Event Randomization, Weeks 1-8 of Cycle 1, Weeks 1-3 of consecutive cycles, 28 days and 3 months after lst treatment, and every 3 months for up to 18 months from last participant randomized | Bevacizumab + Gemcitabine + Erlotinib | 72.2 percentage of participants |
| Placebo + Gemcitabine + Erlotinib | 77.4 percentage of participants | |||
| NCT01214720 | Pancreatic Neoplasms | Duration of Overall Survival - Time to Event Randomization, Weeks 1-8 of Cycle 1, Weeks 1-3 of consecutive cycles, 28 days and 3 months after lst treatment, and every 3 months for up to 18 months from last participant randomized | Bevacizumab + Gemcitabine + Erlotinib | 7.1 months |
| Placebo + Gemcitabine + Erlotinib | 6.0 months | |||
| NCT01236560 | Astrocytoma | Event-free Survival 1 year after enrollment | Arm I (Vorinostat, Phase II Arm A) | 41.3 percent probability |
| Arm II (Temozolomide, Phase II Arm B) | 59.3 percent probability | |||
| Arm III (Bevacizumab, Phase II Arm C) | 43.8 percent probability | |||
| Feasibility (Vorinostat) | 33.3 percent probability | |||
| NCT01236560 | Astrocytoma | Maximum Tolerated Dose (MTD) of Vorinostat 10 weeks | Feasibility (Vorinostat) | 230 mg/sq m |
| NCT01239732 | Ovarian Neoplasms | Percentage of Participants With at Least One Adverse Event (AE) Day 1 up to 30 days after last dose of study treatment (until data cutoff 07 December 2014, up to 4 years) | Bevacizumab + Paclitaxel + Carboplatin | 97.8 percentage of participants |
| NCT01250379 | Breast Neoplasms | Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 12 Month 12 | CT Arm | 16.9 percentage of participants |
| CT+BV Arm | 24.2 percentage of participants | |||
| NCT01250379 | Breast Neoplasms | Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 18 Month 18 | CT Arm | 9.9 percentage of participants |
| CT+BV Arm | 11.0 percentage of participants | |||
| NCT01250379 | Breast Neoplasms | Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 24 Month 24 | CT Arm | 6.4 percentage of participants |
| CT+BV Arm | 6.5 percentage of participants | |||
| NCT01250379 | Breast Neoplasms | Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at Month 6 Month 6 | CT Arm | 40.7 percentage of participants |
| CT+BV Arm | 54.2 percentage of participants | |||
| NCT01250379 | Breast Neoplasms | Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Baseline (less than or equal to [≤] 28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years | CT Arm | 88.7 percentage of participants |
| CT+BV Arm | 93.9 percentage of participants | |||
| NCT01250379 | Breast Neoplasms | Second-Line PFS Baseline (≤28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years | CT Arm | 4.2 months |
| CT+BV Arm | 6.3 months | |||
| NCT01279681 | Colorectal Neoplasms | Progression-Free Survival Up to 5 years | Arm A [Fluoropyrimidine + Bevacizumab (BEV)] | 6.7 months |
| Arm B [Fluoropyrimidine/Oxaliplatin (OXAL) + BEV] | 6.7 months | |||
| NCT01295112 | — | The Primary Efficacy Endpoint is the Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks 24 weeks | Group 1 | 6 Participants |
| Group 1 | 10 Participants | |||
| Group 1 | 13 Participants | |||
| Group 1 | 1 Participants | |||
| Group 1 | 5 Participants | |||
| Group 2 | 11 Participants | |||
| Group 2 | 0 Participants | |||
| Group 2 | 19 Participants | |||
| Group 2 | 3 Participants | |||
| Group 2 | 0 Participants | |||
| NCT01351415 | — | Overall Survival (OS) Up to data cut-off date 24 June 2016 (approximately 5 years) | Bevacizumab + Standard of Care | 11.86 Months |
| Standard of Care | 10.22 Months | |||
| NCT01627249 Protocol T | — | Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69 Baseline to 1-year | Aflibercept | 18.9 units on a scale (±11.5 Standard Deviation) |
| Bevacizumab | 11.8 units on a scale (±12.0 Standard Deviation) | |||
| Ranibizumab | 14.2 units on a scale (±10.6 Standard Deviation) | |||
| NCT01627249 Protocol T | — | Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69 Baseline to 1-year | Aflibercept | 8.0 units on a scale (±7.6 Standard Deviation) |
| Bevacizumab | 7.5 units on a scale (±7.4 Standard Deviation) | |||
| Ranibizumab | 8.3 units on a scale (±6.8 Standard Deviation) | |||
| NCT01627249 Protocol T | — | Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year Baseline to 1-year | Aflibercept | 13.3 units on a scale (±11.1 Standard Deviation) |
| Bevacizumab | 9.7 units on a scale (±10.1 Standard Deviation) | |||
| Ranibizumab | 11.2 units on a scale (±9.4 Standard Deviation) | |||
| NCT01661790 | Carcinoma, Non-Small-Cell Lung | Number of Participants With "Complete Response" and "Partial Response" from randomization, This treatment was given every two weeks,responses were made by biweekly | Bevacizumab & Cisplatin | 13 participants |
| Bevacizumab & Cisplatin | 17 participants | |||
| Cisplatin | 15 participants | |||
| Cisplatin | 2 participants | |||
| NCT01661946 | Macular Edema | Maximum Concentration (Cmax) of Anti-VEGF Antibody 1 month | Bevacizumab | 9.56 ng/mL (±2.50 Standard Error) |
| Ranibizumab | 25.22 ng/mL (±7.59 Standard Error) | |||
| NCT01663727 | Breast Neoplasms | Percentage of Participants With Progression or Death in High Baseline Plasma Vascular Endothelial Growth Factor-A (VEGF-A) ITT Population Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks) | Paclitaxel+ Bevacizumab | 70.8 percentage of participants |
| Paclitaxel+Placebo | 75.0 percentage of participants | |||
| NCT01663727 | Breast Neoplasms | Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks) | Paclitaxel+ Bevacizumab | 63.6 percentage of participants |
| Paclitaxel+Placebo | 69.4 percentage of participants | |||
| NCT01663727 | Breast Neoplasms | PFS in High Baseline Plasma VEGF-A ITT Population Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 111.3 weeks) | Paclitaxel+ Bevacizumab | 9.6 months |
| Paclitaxel+Placebo | 7.3 months | |||
| NCT01663727 | Breast Neoplasms | Progression Free Survival (PFS) in ITT Population Baseline, every 8 weeks until documented disease progression, death or clinical cut-off (up to 117.7 weeks) | Paclitaxel+ Bevacizumab | 11.0 months |
| Paclitaxel+Placebo | 8.8 months | |||
| NCT01718873 OBELICS | Colorectal Neoplasms | Objective Response Rate Objective response was assessed by computed tomographic scan or other appropriate imaging at weeks 12 and 24 from randomization, and every 3 months thereafter, assessed up to 90 months. | Bevacizumab Before Chemotherapy | 65 participants |
| Bevacizumab With Chemotherapy | 66 participants | |||
| NCT01763645 | Carcinoma, Non-Small-Cell Lung | Area Under the Curve After the First Test Drug Administration up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h) | Avastin (F. Hoffmann-La Roche Ltd) | 23970112.875 (ng/ml)*hour |
| BCD-021 (CISC BIOCAD) | 26951463 (ng/ml)*hour | |||
| NCT01763645 | Carcinoma, Non-Small-Cell Lung | Overall Response Rate Day 127 | Avastin (F. Hoffmann-La Roche Ltd) | 33.82 percentage of participans |
| BCD-021 (CISC BIOCAD) | 34.63 percentage of participans | |||
| NCT01940887 | Macular Degeneration | Mean Change in Visual Acuity (Measured at Baseline and at the Month 12 Visit) 12 months | E10030 + Bevacizumab or Aflibercept | 9.42 letters (±0.85 Standard Error) |
| Sham + Bevacizumab or Aflibercept | 9.04 letters (±0.85 Standard Error) | |||
| NCT01966003 | — | Percentage of Participants With an Objective Response Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively. | ABP 215 | 39.0 percentage of participants |
| Bevacizumab | 41.7 percentage of participants | |||
| NCT01969708 SCORE2 | Retinal Vein Occlusion | Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 Month 0 to 6 | Aflibercept | 18.9 letters read |
| Bevacizumab | 18.6 letters read | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Overall Survival (OS) for Cohort 2 Time between the date of randomization and the date of death due to any cause (up to up to 17Jun2019, approximately 5 years) | Cohort 2: Arm B | 10.05 Months |
| Cohort 2: Arm N3 | 9.77 Months | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Percentage of Participants With Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d From first dose to 30 days post last dose (up to approximately 34 months). | Cohort 1: Arm N1+I3 | 20.0 Percentage of participants |
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 70.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 40.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 20.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 25.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 20.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 5.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 50.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 12.9 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 58.1 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 26.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 20.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 33.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 13.3 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 28.6 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 50.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 10.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 21.4 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 35.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 25.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 17.9 Percentage of participants | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who Permanently Discontinued Study Medication Prior to Completing Four Doses Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months) | Cohort 1: Arm N1+I3 | 0 Percentage of participants |
| Cohort 1: Arm N1+I3 | 16.7 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 33.3 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 66.7 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 50.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Percentage of Participants With Serious Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d From first dose to 30 days post last dose (up to approximately 34 months). | Cohort 1: Arm N1+I3 | 0 Percentage of participants |
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 60.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 40.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 35.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 5.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 15.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 45.2 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 16.1 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 35.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 14.3 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 10.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 32.1 Percentage of participants | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Percentage of Participants With Specific Laboratory Abnormalities in Liver Tests in Cohorts 1, 1b, 1c and 1d From first dose to 30 days post last dose (up to approximately 34 months). | Cohort 1: Arm N1+I3 | 10.0 Percentage of participants |
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 5.3 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 10.5 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 5.3 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 15.8 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 12.9 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 10.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 7.4 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 14.8 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| NCT02017717 CheckMate 143 | Glioblastoma | Percentage of Participants With Specific Laboratory Abnormalities in Thyroid Tests in Cohorts 1, 1b, 1c and 1d From first dose to 30 days post last dose (up to approximately 34 months). | Cohort 1: Arm N1+I3 | 20.0 Percentage of participants |
| Cohort 1: Arm N1+I3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 60.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 0.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 60.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N1+I3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 50.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 30.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 10.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 20.0 Percentage of participants | |||
| Cohort 1: Arm N3 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 10.5 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 15.8 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 31.6 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 5.3 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 31.6 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 10.5 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 0.0 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 10.5 Percentage of participants | |||
| Cohort 1b: Arm N3+I1 | 10.5 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 33.3 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 23.3 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 30.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 10.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 20.0 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 13.3 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.7 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.3 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 43.3 Percentage of participants | |||
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 10.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 3.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 13.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 40.0 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 13.3 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 16.7 Percentage of participants | |||
| Part A Cohort 1d: Arm N3+RT | 40.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.7 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 22.2 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 7.4 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 0.0 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 Percentage of participants | |||
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 7.4 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 7.4 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 29.6 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 7.4 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 33.3 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 3.7 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 0.0 Percentage of participants | |||
| Part B Cohort 1d: Arm N3+RT | 18.5 Percentage of participants | |||
| NCT02364999 | Carcinoma, Non-Small-Cell Lung | Objective Response Rate (ORR) by Week 19 25 weeks | Bevacizumab-EU | 44.6 percentage of participants |
| PF-06439535 | 45.3 percentage of participants | |||
| NCT02366143 IMpower150 | Carcinoma, Non-Small-Cell Lung | Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population Baseline until death (up approximately 53 months) | Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 19.0 Months |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 14.7 Months | |||
| NCT02366143 IMpower150 | Carcinoma, Non-Small-Cell Lung | Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months) | Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 19.2 Months |
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 14.7 Months | |||
| NCT02366143 IMpower150 | Carcinoma, Non-Small-Cell Lung | Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months) | Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 8.3 Months |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 11.3 Months | |||
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 6.8 Months | |||
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 6.8 Months | |||
| NCT02394795 PARADIGM | Colorectal Neoplasms | OS in Participants With Left-sided Tumors Up to approximately 60 months | Group B; mFOLFOX6 + Bevacizumab Combination Therapy | 34.30 Months |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy | 37.85 Months | |||
| NCT02394795 PARADIGM | Colorectal Neoplasms | Overall Survival (OS) in All Participants Up to approximately 60 months | Group B; mFOLFOX6 + Bevacizumab Combination Therapy | 31.28 Months |
| Group P; mFOLFOX6 + Panitumumab Combination Therapy | 36.24 Months | |||
| NCT02420821 IMmotion151 | Carcinoma, Renal Cell | Overall Survival (OS) in ITT Population Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months) | Atezolizumab + Bevacizumab | 36.1 months |
| Sunitinib | 35.3 months | |||
| NCT02420821 IMmotion151 | Carcinoma, Renal Cell | Percentage of Participants Who Died of Any Cause in ITT Population Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months) | Atezolizumab + Bevacizumab | 54.8 percentage of participants |
| Sunitinib | 55.3 percentage of participants | |||
| NCT02420821 IMmotion151 | Carcinoma, Renal Cell | Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months) | Atezolizumab + Bevacizumab | 58.4 percentage of participants |
| Sunitinib | 69.6 percentage of participants | |||
| NCT02420821 IMmotion151 | Carcinoma, Renal Cell | Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months) | Atezolizumab + Bevacizumab | 11.2 months |
| Sunitinib | 7.5 months | |||
| NCT02488330 | — | Percentage of Participants With Serious Adverse Events Considered Related to Onartuzumab Baseline through the end of trial (approximately 3 years) | Control and/or Onartuzumab Treatment | 0 Percent |
| NCT02563002 | Colorectal Neoplasms | Overall Survival (OS) Up to approximately 59 months | Pembrolizumab | NA Months |
| Standard of Care (SOC) | 36.7 Months | |||
| NCT02563002 | Colorectal Neoplasms | Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor Up to approximately 59 months | Pembrolizumab | 16.5 Months |
| Standard of Care (SOC) | 8.2 Months | |||
| NCT02753127 CanStem303C | Colorectal Neoplasms | Overall Survival (OS) Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months) | FOLFIRI ± Bevacizumab | 12.12 months |
| FOLFIRI ± Bevacizumab | 13.83 months | |||
| Napabucasin + FOLFIRI ± Bevacizumab | 14.29 months | |||
| Napabucasin + FOLFIRI ± Bevacizumab | 13.17 months | |||
| NCT02754882 | Carcinoma, Non-Small-Cell Lung | Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks 24 weeks from randomisation | Bevacizumab (Avastin) | 42.8 percentage of participants |
| SB8 (A Proposed Bevacizumab Biosimilar) | 47.6 percentage of participants | |||
| NCT02810457 AVANA | Carcinoma, Non-Small-Cell Lung | Overall Response Rate (ORR) Assessed as the Proportion of Patients With a Best Overall Response (BOR) of Either Complete Response (CR) or Partial Response (PR) Until data cut-off, which occurred 12 months after randomization of the last patient enrolled, for a total estimated period of time of up to approximately 30 months. | Avastin / Paclitaxel / Carboplatin | 53.7 percentage of participants |
| FKB238 / Paclitaxel / Carboplatin | 51.6 percentage of participants | |||
| NCT02839707 | Ovarian Neoplasms | Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens Up to 28 days | Arm I (PLD, Atezolizumab) | 0 Participants |
| Arm II (PLD, Bevacizumab, Atezolizumab) | 0 Participants | |||
| Arm III (PLD, Bevacizumab) | 0 Participants | |||
| NCT02839707 | Ovarian Neoplasms | Overall Survival (OS) (Phase III) From study enrollment to the date of death regardless of the cause, assessed up to 5 years | Arm I (PLD, Atezolizumab) | 14.5 months |
| Arm II (PLD, Bevacizumab, Atezolizumab) | 14.9 months | |||
| Arm III (PLD, Bevacizumab) | 12.3 months | |||
| NCT02839707 | Ovarian Neoplasms | PFS (Phase III) From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years. | Arm I (PLD, Atezolizumab) | 4.0 months |
| Arm II (PLD, Bevacizumab, Atezolizumab) | 7.4 months | |||
| Arm III (PLD, Bevacizumab) | 5.6 months | |||
| NCT02839707 | Ovarian Neoplasms | Progression Free Survival (PFS) (Phase II) From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years | Arm I (PLD, Atezolizumab) | 4.2 months |
| Arm II (PLD, Bevacizumab, Atezolizumab) | 7.6 months | |||
| Arm III (PLD, Bevacizumab) | 5.5 months | |||
| NCT02954172 | — | Objective Response Rate 18 weeks | Bevacizumab in Combination With Paclitaxel/Carboplatin | 46.4 percentage of participants |
| IBI305 in Combination With Paclitaxel/Carboplatin | 44.3 percentage of participants | |||
| NCT03038100 IMagyn050 | Ovarian Neoplasms | Overall Survival - ITT Population From randomization up to death from any cause (up to approximately 59 months) | Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 50.53 Months |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | 46.59 Months | |||
| NCT03038100 IMagyn050 | Ovarian Neoplasms | Overall Survival - PD-L1-Positive Subpopulation From randomization up to death from any cause (up to approximately 59 months) | Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | NA Months |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | 49.15 Months | |||
| NCT03038100 IMagyn050 | Ovarian Neoplasms | PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation From randomization until disease progression or death from any cause (up to approximately 55 months) | Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 20.83 Months |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | 18.50 Months | |||
| NCT03038100 IMagyn050 | Ovarian Neoplasms | Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population From randomization until disease progression or death from any cause (up to approximately 55 months) | Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab | 19.48 Months |
| Placebo With Paclitaxel, Carboplatin and Bevacizumab | 18.37 Months | |||
| NCT03117049 | Carcinoma, Non-Small-Cell Lung | Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) Approximately 32 months | ONO-4538 Group | 12.1 months |
| Placebo Group | 8.1 months | |||
| NCT03149003 | Glioblastoma | Number of Participants Who Experienced a Dose-limiting Toxicity Dose-limiting toxicity will be evaluated and applied from Day 1 through Day 29 | Part 1 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab | 0 Participants |
| NCT03149003 | Glioblastoma | Overall Survival (OS) of Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM) Treated With DSP-7888 Dosing Emulsion Plus Bevacizumab (BEV) Versus BEV Alone 4 weeks after the patient has been off study treatment, every 3 months thereafter until death, the study closes, up to 24 months. | Part 2 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab | 10.2 months |
| Part 2 - Arm 2: Bevacizumab | 9.4 months | |||
| NCT03288987 | Colorectal Neoplasms | Progression Free Survival (PFS) PFS was measured from the start of chemotherapy to the date of disease progression or to the date of death if no progression whichever came first, assessed up to 12 months | Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 232 Day (±NA Standard Error) |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 210 Day (±12.21 Standard Error) | |||
| NCT03296163 STELLA | Carcinoma, Non-Small-Cell Lung | Objective Response Rate (ORR) at Week 18 18 weeks from randomisation | EU-approved Avastin® | 44.6 Percentage of participants |
| MB02 (Bevacizumab Biosimilar Drug) | 40.3 Percentage of participants | |||
| NCT03321513 DRCR AC | — | Mean Change in Visual Acuity 2 years | Aflibercept- Monotherapy Group | 15 Letter Score (±8.5 Standard Deviation) |
| Bevacizumab-First Group | 14 Letter Score (±8.8 Standard Deviation) | |||
| NCT03414983 CheckMate 9X8 | Colorectal Neoplasms | Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) From randomization to up to the date of the first documented progression (up to 16 months) | Arm A: NIV+mFOLFOX+BEV | 11.86 Months |
| Arm B: mFOLFOX+BEV | 11.93 Months | |||
| NCT03434379 IMbrave150 | Carcinoma, Hepatocellular | Overall Survival (OS) in the China Population From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months) | Atezolizumab + Bevacizumab - China | NA months |
| Atezolizumab + Bevacizumab - China | 24.05 months | |||
| Sorafenib - China | 11.37 months | |||
| Sorafenib - China | 11.37 months | |||
| NCT03434379 IMbrave150 | Carcinoma, Hepatocellular | Overall Survival (OS) in the Global Population From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months) | Atezolizumab + Bevacizumab - Global | NA months |
| Atezolizumab + Bevacizumab - Global | 19.22 months | |||
| Sorafenib - Global | 13.24 months | |||
| Sorafenib - Global | 13.40 months | |||
| NCT03434379 IMbrave150 | Carcinoma, Hepatocellular | PFS-IRF Per RECIST v1.1 in the China Population Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months) | Atezolizumab + Bevacizumab - China | 5.72 months |
| Sorafenib - China | 3.19 months | |||
| NCT03434379 IMbrave150 | Carcinoma, Hepatocellular | Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months) | Atezolizumab + Bevacizumab - Global | 6.83 months |
| Sorafenib - Global | 4.27 months | |||
| NCT03635489 | Ovarian Neoplasms | Progression-Free Survival (PFS) Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months) | Bevacizumab + Paclitaxel + Carboplatin | 22.57 months |
| Placebo + Paclitaxel + Carboplatin | 12.32 months | |||
| NCT03635567 | Uterine Cervical Neoplasms | OS in All Participants Up to approximately 46 months | Pembrolizumab+Chemotherapy | 26.4 Months |
| Placebo+Chemotherapy | 16.8 Months | |||
| NCT03635567 | Uterine Cervical Neoplasms | OS in Participants With PD-L1 CPS ≥10 Up to approximately 46 months | Pembrolizumab+Chemotherapy | 29.6 Months |
| Placebo+Chemotherapy | 17.4 Months | |||
| NCT03635567 | Uterine Cervical Neoplasms | Overall Survival (OS) in Participants With PD-L1 CPS ≥1 Up to approximately 46 months | Pembrolizumab+Chemotherapy | 28.6 Months |
| Placebo+Chemotherapy | 16.5 Months | |||
| NCT03635567 | Uterine Cervical Neoplasms | PFS Per RECIST 1.1 as Assessed by Investigator in All Participants Up to approximately 46 months | Pembrolizumab+Chemotherapy | 10.4 Months |
| Placebo+Chemotherapy | 8.2 Months | |||
| NCT03635567 | Uterine Cervical Neoplasms | PFS Per RECIST 1.1 as Assessed by Investigator in Participants With PD-L1 CPS ≥10 Up to approximately 46 months | Pembrolizumab+Chemotherapy | 10.4 Months |
| Placebo+Chemotherapy | 8.1 Months | |||
| NCT03635567 | Uterine Cervical Neoplasms | Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Up to approximately 46 months | Pembrolizumab+Chemotherapy | 10.5 Months |
| Placebo+Chemotherapy | 8.2 Months | |||
| NCT03740165 | Ovarian Neoplasms | PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants Up to approximately 67 months | Carboplatin + Paclitaxel | 14.6 Months |
| Carboplatin + Paclitaxel + Pembrolizumab | 15.2 Months | |||
| Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 22.2 Months | |||
| NCT03740165 | Ovarian Neoplasms | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10) Up to approximately 67 months | Carboplatin + Paclitaxel | 15.2 Months |
| Carboplatin + Paclitaxel + Pembrolizumab | 17.3 Months | |||
| Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 23.9 Months | |||
| NCT03762018 BEAT-meso | — | Overall Survival (OS) From randomization until death from any cause, up to 52 months. | Atezolizumab Plus Bevacizumab Plus Chemotherapy | 20.5 months |
| Bevacizumab Plus Chemotherapy | 18.1 months | |||
| NCT04008030 CheckMate 8HW | Colorectal Neoplasms | Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months) | Arm A - Nivolumab Monotherapy | 39.26 Months |
| Arm B - Nivolumab + Ipilimumab | NA Months | |||
| NCT04008030 CheckMate 8HW | Colorectal Neoplasms | Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months) | Arm B - Nivolumab + Ipilimumab | NA Months |
| Arm C - Investigator's Choice Chemotherapy | 5.85 Months | |||
| NCT04094688 SOLARIS | — | Progression-free Survival (PFS) 4 years | Arm I (Bevacizumab, Chemotherapy, High-dose Vitamin D3) | 11.8 months |
| Arm II (Bevacizumab, Chemotherapy, Standard-dose Vitamin D3) | 10.3 months | |||
| NCT04102098 IMbrave050 | Carcinoma, Hepatocellular | Recurrence-Free Survival (RFS), as Determined by IRF Baseline up to approximately 33 months | Arm A (Atezolizumab Plus Bevacizumab) | NA Months |
| Arm B (Active Surveillance) | NA Months | |||
| NCT04456699 | Colorectal Neoplasms | Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) Up to approximately 30 months | Bevacizumab + Chemotherapy | 5.5 Months |
| Olaparib | 3.6 Months | |||
| Olaparib + Bevacizumab | 3.7 Months | |||
| NCT04487067 AMETHISTA | Carcinoma, Hepatocellular | Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage Up to approximately 47.6 months | Atezolizumab + Bevacizumab | 17 Participants |
| Atezolizumab + Bevacizumab | 3 Participants | |||
| Atezolizumab + Bevacizumab | 2 Participants | |||
| NCT04633564 | Carcinoma, Non-Small-Cell Lung | Primary Efficacy Analysis of Overall Response Rate ( ORR) of MYL-1402O as Compared to Avastin 18 weeks after first dosing per patient | Avastin | 144 Participants |
| Avastin | 190 Participants | |||
| MYL-1402O | 197 Participants | |||
| MYL-1402O | 140 Participants | |||
| NCT04634604 ROP3 | Retinopathy of Prematurity | Treatment Success Rate At 6 Months Adjusted Age 6 Months Adjusted Age | Bevacizumab | 3 Participants |
| Laser | 4 Participants | |||
| NCT04732286 | Carcinoma, Hepatocellular | Number of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 3 From Cycle 1 Day 1 up to 30 days after the final dose of the study drug or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 32 months) | Atezolizumab + Bevacizumab | 19 Participants |
| NCT04737187 SUNLIGHT | Colorectal Neoplasms | Overall Survival (OS) From date of randomization to the death due to any cause or cut-off date, whichever comes first (maximum duration: up to 20 months) | Trifluridine/Tipiracil | 7.46 months |
| Trifluridine/Tipiracil + Bevacizumab | 10.78 months | |||
| NCT04737187 SUNLIGHT | Colorectal Neoplasms | Survival Probability at 12 Months From date of randomization until 12 months post treatment | Trifluridine/Tipiracil | 0.30 probability of participants |
| Trifluridine/Tipiracil + Bevacizumab | 0.43 probability of participants | |||
| NCT04737187 SUNLIGHT | Colorectal Neoplasms | Survival Probability at 18 Months From date of randomization until 18 months post treatment | Trifluridine/Tipiracil | 0.15 probability of participants |
| Trifluridine/Tipiracil + Bevacizumab | 0.28 probability of participants | |||
| NCT04737187 SUNLIGHT | Colorectal Neoplasms | Survival Probability at 6 Months From date of randomization until 6 months post treatment | Trifluridine/Tipiracil | 0.61 probability of participants |
| Trifluridine/Tipiracil + Bevacizumab | 0.77 probability of participants | |||
| NCT05116189 | Ovarian Neoplasms | PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants Up to ~38 months | Pembrolizumab + Paclitaxel ± Bevacizumab | 8.3 Months |
| Placebo + Paclitaxel ± Bevacizumab | 6.4 Months | |||
| NCT05116189 | Ovarian Neoplasms | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥1) Up to ~38 months | Pembrolizumab + Paclitaxel ± Bevacizumab | 8.3 Months |
| Placebo + Paclitaxel ± Bevacizumab | 7.2 Months | |||
| NCT05718466 | Glioblastoma | Local Tumor Control 2 months | Bev With Chemo | 4 Participants |
| Fractionated Radiosurgery and Bevacizumab | 14 Participants | |||
| NCT05718466 | Glioblastoma | Overall Survival 12 months | Bev With Chemo | 4.8 months |
| Fractionated Radiosurgery and Bevacizumab | 7.2 months | |||
| NCT05718466 | Glioblastoma | Progression Free Survival 12 months | Bev With Chemo | 1.8 months |
| Fractionated Radiosurgery and Bevacizumab | 5.1 months |